David L. Kemmerly Sells 3,375 Shares of Amedisys Inc (AMED) Stock

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 3,375 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $117.44, for a total transaction of $396,360.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

David L. Kemmerly also recently made the following trade(s):

  • On Friday, November 9th, David L. Kemmerly sold 6,500 shares of Amedisys stock. The stock was sold at an average price of $118.87, for a total transaction of $772,655.00.

Shares of NASDAQ AMED traded up $1.46 during midday trading on Friday, hitting $120.50. The company had a trading volume of 476,741 shares, compared to its average volume of 654,049. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. Amedisys Inc has a twelve month low of $49.80 and a twelve month high of $127.38. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of 54.52, a price-to-earnings-growth ratio of 1.76 and a beta of 1.22.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.18. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The firm had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. During the same quarter last year, the business earned $0.56 earnings per share. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. Equities research analysts expect that Amedisys Inc will post 3.58 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Amedisys by 7.5% in the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after purchasing an additional 377,153 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Amedisys by 14.6% in the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after purchasing an additional 118,936 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Amedisys by 218.9% in the third quarter. Acadian Asset Management LLC now owns 609,586 shares of the health services provider’s stock valued at $76,177,000 after purchasing an additional 418,424 shares during the period. Rothschild Asset Management Inc. lifted its stake in shares of Amedisys by 0.3% in the second quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock valued at $38,223,000 after purchasing an additional 1,278 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of Amedisys by 141.4% in the third quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock valued at $49,551,000 after purchasing an additional 232,255 shares during the period. Hedge funds and other institutional investors own 93.58% of the company’s stock.

Several analysts have recently commented on AMED shares. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Craig Hallum cut shares of Amedisys from a “buy” rating to a “hold” rating and reduced their target price for the stock from $116.00 to $104.00 in a research note on Friday, October 26th. Canaccord Genuity started coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. SunTrust Banks raised their target price on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Finally, Benchmark upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 target price for the company in a research note on Tuesday, October 30th. Five analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Amedisys has an average rating of “Buy” and an average price target of $105.50.

WARNING: “David L. Kemmerly Sells 3,375 Shares of Amedisys Inc (AMED) Stock” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2018/11/10/david-l-kemmerly-sells-3375-shares-of-amedisys-inc-amed-stock.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Article: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply